Lavinia Fabeni

Lavinia Fabeni

National Institute for Infectious Diseases Lazzaro Spllanzani - Rome / Italy
Others
AD Scientific Index ID: 5083379
Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani
person_outline Lavinia Fabeni's MOST POPULAR ARTICLES
1-) Characterization and structural analysis of HIV-1 integrase conservationF Ceccherini-Silberstein, I Malet, R D\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\'Arrigo, A Antinori, AG Marcelin, ...AIDS Rev 11 (1), 17-29, 20091742009
2-) Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levelsMM Santoro, L Fabeni, D Armenia, C Alteri, D Di Pinto, F Forbici, A Bertoli, ...Clinical infectious diseases 58 (8), 1156-1164, 2014812014
3-) Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencingD Armenia, I Vandenbroucke, L Fabeni, H Van Marck, V Cento, R D’Arrigo, ...Journal of Infectious Diseases 205 (4), 557-567, 2012722012
4-) Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitorsF Ceccherini-Silberstein, I Malet, L Fabeni, S Dimonte, V Svicher, ...Journal of antimicrobial chemotherapy 65 (11), 2305-2318, 2010632010
5-) Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitorsF Ceccherini-Silberstein, K Van Baelen, D Armenia, M Trignetti, ...Antimicrobial agents and chemotherapy 54 (9), 3938-3948, 2010562010